The R3i is led by a Board of Trustees and an International Steering Committee (ISC) of officers and members from the disciplines of cardiology, diabetology, lipidology, endocrinology, epidemiology, nutrition, ophthalmology, nephrology and basic science.

Prof. Michel Hermans

General Secretary

Prof. Lale Tokgozoglu

Board member

February 28, 2025

It is my honor to have been selected as the President of the Residual Risk Reduction Initiative (R3i.) This foundation is dedicated to combatting cardiovascular disease, the number one killer and contributor to loss of productive life years globally. We are fortunate to possess an extensive toolkit of interventions to attack the traditional risk factors for atherosclerotic cardiovascular disease, a major manifestation of this constellation of conditions. Yet, with the spreading epidemic of obesity and diabetes and the epidemiologic transition in low- and middle-income countries leading to replacement of chronic cardiovascular disease versus communicable diseases, we face a growing challenge of cardiometabolic risk. Further progress in reducing morbidity and mortality due to cardiovascular disease globally will require not only research to identify new targets and develop new therapies but also implementation and efforts to control emerging threats to cardiovascular and other aspects of health. These challenges include air, noise, and light pollution, the ubiquity of nanoplastics, and healthcare disparities based on geographical and socio-economic status. I am passionate about the R3i initiative to attack residual risk that persists despite current therapies and the Foundation’s multi-pronged approach to this mission that unites academia, practitioners, the pharmaceutical industry, and biotechnology enterprises in a united effort towards these ends. We will strive to include patient voices as we face the future and continue our core commitment to diversity and a global reach.

R3i was founded by the visionary Jean-Charles Fruchart who presided this organization until his untimely death. I assume the mantle of leadership of this important initiative, with great humility and devotion, to better human knowledge and promote public health and the conquest of cardiovascular disease.

Sincerely yours,

Peter Libby, MD

Prof. Alberto J. Lorenzatti

Prof. Chérif Abdelkhirane

Prof. Jorge Plutzky

Prof. Michal Vrablík

Prof. Robert H. Eckel

Prof. Ulrich Laufs

Prof. Yoshihiro Fukumoto

Prof. Henri Ginsberg